Additionally, the use of G-CSF/GM-CSF (42% vs 37%), antibiotics (39% vs 32%), antifungals (14% vs 8%), and antihypertensive agents (25% vs. 18%) was numerically higher in the ramucirumab arm, in line with the higher incidence of neutropenia (49% vs 39%), febrile neutropenia (16% vs 10%), severe infections (26% vs 20%), and treatment-emergent hypertension (6% vs 2%) in that arm versus the control arm. Here, CSF3 is linked to infection.